Loading…

Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR

The specific human epidermal growth factor receptor 2 (HER2)-targeting monoclonal antibody trastuzumab shows considerable clinical efficacy in patients with HER2-overexpressing breast cancer. However, about 20% of patients who receive trastuzumab in the adjuvant setting relapse, and approximately ha...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2022-01, Vol.588, p.175-181
Main Authors: Yang, Lili, Higashisaka, Kazuma, Shimoda, Masafumi, Haga, Yuya, Sekine, Naoki, Tsujino, Hirofumi, Nagano, Kazuya, Shimazu, Kenzo, Tsutsumi, Yasuo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c400t-e787d0f93055d20c870348e711a00d61d8332491c5bcf62a6493dfcac31ceda23
cites cdi_FETCH-LOGICAL-c400t-e787d0f93055d20c870348e711a00d61d8332491c5bcf62a6493dfcac31ceda23
container_end_page 181
container_issue
container_start_page 175
container_title Biochemical and biophysical research communications
container_volume 588
creator Yang, Lili
Higashisaka, Kazuma
Shimoda, Masafumi
Haga, Yuya
Sekine, Naoki
Tsujino, Hirofumi
Nagano, Kazuya
Shimazu, Kenzo
Tsutsumi, Yasuo
description The specific human epidermal growth factor receptor 2 (HER2)-targeting monoclonal antibody trastuzumab shows considerable clinical efficacy in patients with HER2-overexpressing breast cancer. However, about 20% of patients who receive trastuzumab in the adjuvant setting relapse, and approximately half of patients with metastatic HER2-positive breast cancer develop resistance to trastuzumab within 1 year. Although the mechanism of trastuzumab resistance has been explored broadly, whether and how angiogenesis participates in trastuzumab resistance is unclear. Here, we examined the association between angiogenesis and trastuzumab resistance by using a trastuzumab-resistant cell line (SKBR3-TR). Compared with that from the parental trastuzumab-sensitive SKBR3 cells, the culture supernatant from SKBR3-TR cells significantly increased the sprouting of endothelial cells. To identify intercellular features that contribute to the induction of endothelial tube formation, proteomics revealed that α-crystallin B chain (αB-crystallin) was upregulated in SKBR3-TR cells. Moreover, silencing of αB-crystallin significantly repressed SKBR3-TR-induced tube formation, and knockdown of αB-crystallin in SKBR3-TR cells suppressed the activation of mechanistic target of rapamycin (mTOR) in endothelial cells. In addition, treatment with rapamycin, an inhibitor of mTOR, reversed the SKBR3-TR-induced promotion of tube formation. In summary, αB-crystallin enhanced the ability of SKBR3-TR cells to activate mTOR in endothelial cells and thus promote angiogenesis. •Increased αB-crystallin level of SKBR3-TR cells promoted tube formation by HAECs.•Silencing αB-crystallin in SKBR3-TR cells suppresses p-mTOR in endothelial cells.•Rapamycin suppressed tube formation in HAECs induced by SKBR3-TR cells.
doi_str_mv 10.1016/j.bbrc.2021.12.056
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2615117992</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X21016910</els_id><sourcerecordid>2615117992</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-e787d0f93055d20c870348e711a00d61d8332491c5bcf62a6493dfcac31ceda23</originalsourceid><addsrcrecordid>eNp9kMtu1TAQhi0EoofCC7BAXrJJmHFuxxKbUnGTKlVCRWJnOfak8VESH2ynUvsAPDcOp7BkNaPxN7_GH2OvEUoEbN8dyr4PphQgsERRQtM-YTsECYVAqJ-yHQC0hZD444y9iPEAgFi38jk7q2rZSJSwY78upuOoCxPuY9LT5Bb-gZtRuyXy3KegY1of1ln3RaDoMrMk3gfKY270YihwQ9MU-TH42SfitFifRpqcnv688LT2xAcfZp2cz4lj8OvtyLVJ7i6Plls-31x_e8meDXqK9OqxnrPvnz7eXH4prq4_f728uCpMDZAK6vadhUFW0DRWgNl3UNV76hA1gG3R7qtK1BJN05uhFbqtZWUHo02FhqwW1Tl7e8rN9_5cKSY1u7jdqRfya1SixQaxk3JDxQk1wccYaFDH4GYd7hWC2vyrg9r8q82_QqGy_7z05jF_7Wey_1b-Cs_A-xNA-Zd3joKKxlEWaV0gk5T17n_5vwFXPJlV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2615117992</pqid></control><display><type>article</type><title>Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Yang, Lili ; Higashisaka, Kazuma ; Shimoda, Masafumi ; Haga, Yuya ; Sekine, Naoki ; Tsujino, Hirofumi ; Nagano, Kazuya ; Shimazu, Kenzo ; Tsutsumi, Yasuo</creator><creatorcontrib>Yang, Lili ; Higashisaka, Kazuma ; Shimoda, Masafumi ; Haga, Yuya ; Sekine, Naoki ; Tsujino, Hirofumi ; Nagano, Kazuya ; Shimazu, Kenzo ; Tsutsumi, Yasuo</creatorcontrib><description>The specific human epidermal growth factor receptor 2 (HER2)-targeting monoclonal antibody trastuzumab shows considerable clinical efficacy in patients with HER2-overexpressing breast cancer. However, about 20% of patients who receive trastuzumab in the adjuvant setting relapse, and approximately half of patients with metastatic HER2-positive breast cancer develop resistance to trastuzumab within 1 year. Although the mechanism of trastuzumab resistance has been explored broadly, whether and how angiogenesis participates in trastuzumab resistance is unclear. Here, we examined the association between angiogenesis and trastuzumab resistance by using a trastuzumab-resistant cell line (SKBR3-TR). Compared with that from the parental trastuzumab-sensitive SKBR3 cells, the culture supernatant from SKBR3-TR cells significantly increased the sprouting of endothelial cells. To identify intercellular features that contribute to the induction of endothelial tube formation, proteomics revealed that α-crystallin B chain (αB-crystallin) was upregulated in SKBR3-TR cells. Moreover, silencing of αB-crystallin significantly repressed SKBR3-TR-induced tube formation, and knockdown of αB-crystallin in SKBR3-TR cells suppressed the activation of mechanistic target of rapamycin (mTOR) in endothelial cells. In addition, treatment with rapamycin, an inhibitor of mTOR, reversed the SKBR3-TR-induced promotion of tube formation. In summary, αB-crystallin enhanced the ability of SKBR3-TR cells to activate mTOR in endothelial cells and thus promote angiogenesis. •Increased αB-crystallin level of SKBR3-TR cells promoted tube formation by HAECs.•Silencing αB-crystallin in SKBR3-TR cells suppresses p-mTOR in endothelial cells.•Rapamycin suppressed tube formation in HAECs induced by SKBR3-TR cells.</description><identifier>ISSN: 0006-291X</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2021.12.056</identifier><identifier>PMID: 34959190</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>alpha-Crystallin B Chain - metabolism ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Cell Line, Tumor ; Culture Media, Conditioned - pharmacology ; Drug Resistance, Neoplasm - drug effects ; Endothelial cell tube formation ; Endothelial Cells - drug effects ; Endothelial Cells - metabolism ; Female ; HER2-Positive breast cancer ; Humans ; Neovascularization, Physiologic - drug effects ; Phosphorylation - drug effects ; TOR Serine-Threonine Kinases - metabolism ; Trastuzumab - pharmacology ; Trastuzumab - therapeutic use ; Trastuzumab resistance ; αB-crystallin</subject><ispartof>Biochemical and biophysical research communications, 2022-01, Vol.588, p.175-181</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-e787d0f93055d20c870348e711a00d61d8332491c5bcf62a6493dfcac31ceda23</citedby><cites>FETCH-LOGICAL-c400t-e787d0f93055d20c870348e711a00d61d8332491c5bcf62a6493dfcac31ceda23</cites><orcidid>0000-0002-0832-9877 ; 0000-0002-0837-2357 ; 0000-0001-5435-5462 ; 0000-0003-4148-2256 ; 0000-0001-9473-8302</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34959190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Lili</creatorcontrib><creatorcontrib>Higashisaka, Kazuma</creatorcontrib><creatorcontrib>Shimoda, Masafumi</creatorcontrib><creatorcontrib>Haga, Yuya</creatorcontrib><creatorcontrib>Sekine, Naoki</creatorcontrib><creatorcontrib>Tsujino, Hirofumi</creatorcontrib><creatorcontrib>Nagano, Kazuya</creatorcontrib><creatorcontrib>Shimazu, Kenzo</creatorcontrib><creatorcontrib>Tsutsumi, Yasuo</creatorcontrib><title>Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>The specific human epidermal growth factor receptor 2 (HER2)-targeting monoclonal antibody trastuzumab shows considerable clinical efficacy in patients with HER2-overexpressing breast cancer. However, about 20% of patients who receive trastuzumab in the adjuvant setting relapse, and approximately half of patients with metastatic HER2-positive breast cancer develop resistance to trastuzumab within 1 year. Although the mechanism of trastuzumab resistance has been explored broadly, whether and how angiogenesis participates in trastuzumab resistance is unclear. Here, we examined the association between angiogenesis and trastuzumab resistance by using a trastuzumab-resistant cell line (SKBR3-TR). Compared with that from the parental trastuzumab-sensitive SKBR3 cells, the culture supernatant from SKBR3-TR cells significantly increased the sprouting of endothelial cells. To identify intercellular features that contribute to the induction of endothelial tube formation, proteomics revealed that α-crystallin B chain (αB-crystallin) was upregulated in SKBR3-TR cells. Moreover, silencing of αB-crystallin significantly repressed SKBR3-TR-induced tube formation, and knockdown of αB-crystallin in SKBR3-TR cells suppressed the activation of mechanistic target of rapamycin (mTOR) in endothelial cells. In addition, treatment with rapamycin, an inhibitor of mTOR, reversed the SKBR3-TR-induced promotion of tube formation. In summary, αB-crystallin enhanced the ability of SKBR3-TR cells to activate mTOR in endothelial cells and thus promote angiogenesis. •Increased αB-crystallin level of SKBR3-TR cells promoted tube formation by HAECs.•Silencing αB-crystallin in SKBR3-TR cells suppresses p-mTOR in endothelial cells.•Rapamycin suppressed tube formation in HAECs induced by SKBR3-TR cells.</description><subject>alpha-Crystallin B Chain - metabolism</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Cell Line, Tumor</subject><subject>Culture Media, Conditioned - pharmacology</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Endothelial cell tube formation</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - metabolism</subject><subject>Female</subject><subject>HER2-Positive breast cancer</subject><subject>Humans</subject><subject>Neovascularization, Physiologic - drug effects</subject><subject>Phosphorylation - drug effects</subject><subject>TOR Serine-Threonine Kinases - metabolism</subject><subject>Trastuzumab - pharmacology</subject><subject>Trastuzumab - therapeutic use</subject><subject>Trastuzumab resistance</subject><subject>αB-crystallin</subject><issn>0006-291X</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMtu1TAQhi0EoofCC7BAXrJJmHFuxxKbUnGTKlVCRWJnOfak8VESH2ynUvsAPDcOp7BkNaPxN7_GH2OvEUoEbN8dyr4PphQgsERRQtM-YTsECYVAqJ-yHQC0hZD444y9iPEAgFi38jk7q2rZSJSwY78upuOoCxPuY9LT5Bb-gZtRuyXy3KegY1of1ln3RaDoMrMk3gfKY270YihwQ9MU-TH42SfitFifRpqcnv688LT2xAcfZp2cz4lj8OvtyLVJ7i6Plls-31x_e8meDXqK9OqxnrPvnz7eXH4prq4_f728uCpMDZAK6vadhUFW0DRWgNl3UNV76hA1gG3R7qtK1BJN05uhFbqtZWUHo02FhqwW1Tl7e8rN9_5cKSY1u7jdqRfya1SixQaxk3JDxQk1wccYaFDH4GYd7hWC2vyrg9r8q82_QqGy_7z05jF_7Wey_1b-Cs_A-xNA-Zd3joKKxlEWaV0gk5T17n_5vwFXPJlV</recordid><startdate>20220115</startdate><enddate>20220115</enddate><creator>Yang, Lili</creator><creator>Higashisaka, Kazuma</creator><creator>Shimoda, Masafumi</creator><creator>Haga, Yuya</creator><creator>Sekine, Naoki</creator><creator>Tsujino, Hirofumi</creator><creator>Nagano, Kazuya</creator><creator>Shimazu, Kenzo</creator><creator>Tsutsumi, Yasuo</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0832-9877</orcidid><orcidid>https://orcid.org/0000-0002-0837-2357</orcidid><orcidid>https://orcid.org/0000-0001-5435-5462</orcidid><orcidid>https://orcid.org/0000-0003-4148-2256</orcidid><orcidid>https://orcid.org/0000-0001-9473-8302</orcidid></search><sort><creationdate>20220115</creationdate><title>Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR</title><author>Yang, Lili ; Higashisaka, Kazuma ; Shimoda, Masafumi ; Haga, Yuya ; Sekine, Naoki ; Tsujino, Hirofumi ; Nagano, Kazuya ; Shimazu, Kenzo ; Tsutsumi, Yasuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-e787d0f93055d20c870348e711a00d61d8332491c5bcf62a6493dfcac31ceda23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>alpha-Crystallin B Chain - metabolism</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Cell Line, Tumor</topic><topic>Culture Media, Conditioned - pharmacology</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Endothelial cell tube formation</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - metabolism</topic><topic>Female</topic><topic>HER2-Positive breast cancer</topic><topic>Humans</topic><topic>Neovascularization, Physiologic - drug effects</topic><topic>Phosphorylation - drug effects</topic><topic>TOR Serine-Threonine Kinases - metabolism</topic><topic>Trastuzumab - pharmacology</topic><topic>Trastuzumab - therapeutic use</topic><topic>Trastuzumab resistance</topic><topic>αB-crystallin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Lili</creatorcontrib><creatorcontrib>Higashisaka, Kazuma</creatorcontrib><creatorcontrib>Shimoda, Masafumi</creatorcontrib><creatorcontrib>Haga, Yuya</creatorcontrib><creatorcontrib>Sekine, Naoki</creatorcontrib><creatorcontrib>Tsujino, Hirofumi</creatorcontrib><creatorcontrib>Nagano, Kazuya</creatorcontrib><creatorcontrib>Shimazu, Kenzo</creatorcontrib><creatorcontrib>Tsutsumi, Yasuo</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Lili</au><au>Higashisaka, Kazuma</au><au>Shimoda, Masafumi</au><au>Haga, Yuya</au><au>Sekine, Naoki</au><au>Tsujino, Hirofumi</au><au>Nagano, Kazuya</au><au>Shimazu, Kenzo</au><au>Tsutsumi, Yasuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2022-01-15</date><risdate>2022</risdate><volume>588</volume><spage>175</spage><epage>181</epage><pages>175-181</pages><issn>0006-291X</issn><eissn>1090-2104</eissn><abstract>The specific human epidermal growth factor receptor 2 (HER2)-targeting monoclonal antibody trastuzumab shows considerable clinical efficacy in patients with HER2-overexpressing breast cancer. However, about 20% of patients who receive trastuzumab in the adjuvant setting relapse, and approximately half of patients with metastatic HER2-positive breast cancer develop resistance to trastuzumab within 1 year. Although the mechanism of trastuzumab resistance has been explored broadly, whether and how angiogenesis participates in trastuzumab resistance is unclear. Here, we examined the association between angiogenesis and trastuzumab resistance by using a trastuzumab-resistant cell line (SKBR3-TR). Compared with that from the parental trastuzumab-sensitive SKBR3 cells, the culture supernatant from SKBR3-TR cells significantly increased the sprouting of endothelial cells. To identify intercellular features that contribute to the induction of endothelial tube formation, proteomics revealed that α-crystallin B chain (αB-crystallin) was upregulated in SKBR3-TR cells. Moreover, silencing of αB-crystallin significantly repressed SKBR3-TR-induced tube formation, and knockdown of αB-crystallin in SKBR3-TR cells suppressed the activation of mechanistic target of rapamycin (mTOR) in endothelial cells. In addition, treatment with rapamycin, an inhibitor of mTOR, reversed the SKBR3-TR-induced promotion of tube formation. In summary, αB-crystallin enhanced the ability of SKBR3-TR cells to activate mTOR in endothelial cells and thus promote angiogenesis. •Increased αB-crystallin level of SKBR3-TR cells promoted tube formation by HAECs.•Silencing αB-crystallin in SKBR3-TR cells suppresses p-mTOR in endothelial cells.•Rapamycin suppressed tube formation in HAECs induced by SKBR3-TR cells.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34959190</pmid><doi>10.1016/j.bbrc.2021.12.056</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0832-9877</orcidid><orcidid>https://orcid.org/0000-0002-0837-2357</orcidid><orcidid>https://orcid.org/0000-0001-5435-5462</orcidid><orcidid>https://orcid.org/0000-0003-4148-2256</orcidid><orcidid>https://orcid.org/0000-0001-9473-8302</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-291X
ispartof Biochemical and biophysical research communications, 2022-01, Vol.588, p.175-181
issn 0006-291X
1090-2104
language eng
recordid cdi_proquest_miscellaneous_2615117992
source ScienceDirect Freedom Collection 2022-2024
subjects alpha-Crystallin B Chain - metabolism
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cell Line, Tumor
Culture Media, Conditioned - pharmacology
Drug Resistance, Neoplasm - drug effects
Endothelial cell tube formation
Endothelial Cells - drug effects
Endothelial Cells - metabolism
Female
HER2-Positive breast cancer
Humans
Neovascularization, Physiologic - drug effects
Phosphorylation - drug effects
TOR Serine-Threonine Kinases - metabolism
Trastuzumab - pharmacology
Trastuzumab - therapeutic use
Trastuzumab resistance
αB-crystallin
title Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T12%3A01%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alpha-crystallin%20B%20chains%20in%20trastuzumab-resistant%20breast%20cancer%20cells%20promote%20endothelial%20cell%20tube%20formation%20through%20activating%20mTOR&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Yang,%20Lili&rft.date=2022-01-15&rft.volume=588&rft.spage=175&rft.epage=181&rft.pages=175-181&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2021.12.056&rft_dat=%3Cproquest_cross%3E2615117992%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-e787d0f93055d20c870348e711a00d61d8332491c5bcf62a6493dfcac31ceda23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2615117992&rft_id=info:pmid/34959190&rfr_iscdi=true